Is PMGC Holdings Inc. (ELAB) a Buy, Sell, or Hold?
PMGC Holdings Inc.
NASDAQ:ELAB
$1.08 USD
-$0.04 (-3.57%)
- Volume
- 3.73M
- Average Volume
- 3.19M
- Market Capitalization
- $2.09M
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $309.89
- Year Low
- $1.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.45
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Graydon Bensler |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ELAB |
| CUSIP | 73017P508 |
| CIK | 0001840563 |
| Web | https://pmgcholdings.com |
| Phone | 866 445 4886 |
| Currency | USD |
| Employees | 34 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.63 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.45 |
| Quick Ratio | 1.43 |
| Cash Ratio | 1.27 |
Sales & Book Value
| Annual Sales | $590.08K |
| Price / Sales | 1.64 |
| Cash Flow | -18.83 |
| Price / Cash Flow | -0.25 |
| Price / Book | 0.04 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-378.74 |
| Trailing P/E Ratio | 0.00 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-7.71M |
| Net Margin | -873.11% |
| Pretax Margin | -876.97% |
| Return on Equity | -116.96% |
| Return on Assets | -42.66% |
Financials Score
| AltmanZ Score | -2.20 |
| Piotroski Score | 3.00 |
| Working Capital | 5.09M |
| Total Assets | 26.03M |
| Ebit | -9.29M |
| Market Cap | 2.09M |
| Total Liabilities | 13.43M |
Poll Results
About PMGC Holdings Inc. (NASDAQ:ELAB) Stock
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California. ...
2026-07-13 07:30:00
Definitive license agreement formalizes exclusive, worldwide, sublicensable rights to patented multi-domain drone payload technology for aerospace and defense applications Agreement follows the binding term sheet and sponsored research agreement announced earlier this year License covers U. S. Patent No. 12,291,334 and related know-how, with a multi-year development plan targeting prototype completion, non-dilutive funding applications, and first commercial sale NEWPORT BEACH, Calif.
2026-07-13 07:30:00
NorthStrive Defense Tech Executes Definitive Exclusive License Agreement with Florida State University Research Foundation for Multi-Domain Drone Payload T
2026-07-10 07:30:00
Independent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously manufactured by MOA Life Plus Co. Ltd. Work is intended to strengthen EL-22 product identity and manufacturing consistency as NorthStrive advances a differentiated engineered probiotic designed to help preserve muscle during weight loss, including with GLP-1 receptor agonists NEWPORT BEACH, Calif.
PMGC Holdings Inc. Announces Merger of AGA Precision Systems into A&B Aerospace
2026-07-06 07:30:00
Strategic consolidation of two precision manufacturing portfolio companies expected to streamline operations, shared resources, and strengthen the companies' aerospace manufacturing platform NEWPORT BEACH, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced that it has merged AGA Precision Systems LLC (“AGA”) into A&B Aerospace, Inc. (“A&B Aerospace”), with A&B Aerospace expected to be the surviving operating entity.
Wall Street is Watching These Biotechs
2026-07-01 09:32:00
Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDAQ: ELAB) are pursuing a distinct therapeutic strategy
2026-07-01 07:30:00
Yuva Biosciences' proprietary MitoNova™ AI platform identified small-molecule candidates that were biologically validated in primary human skeletal muscle cells, with multiple candidates increasing ANT1, a mitochondrial protein central to skeletal muscle energy metabolism. Four AI-selected compounds demonstrated ANT1 induction, supporting their further confirmatory testing and development.
2026-06-18 07:30:00
Filed applications include claims directed to the use of EL-22 and EL-32 for preserving lean muscle mass during GLP-1 and obesity-related weight loss Filed applications include combination and co-administration approaches, including taking EL-22 or EL-32 together with apelin or ursolic acid, compounds associated with muscle support NEWPORT BEACH, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("PMGC" or the "Company") today announced that its wholly-owned subsidiary, NorthStrive Biosciences, Inc. ("NorthStrive"), has filed two new U.S. patent applications expanding the Company's EL-22 and EL-32 intellectual property portfolio into potential human pharmaceutical applications for the preservation of lean muscle mass during GLP-1 and obesity-related weight loss.
2026-06-10 07:31:00
A&B Aerospace, SVM Machining, and AGA Precision Systems Position PMGC's Precision Manufacturing Platform to Serve Growing Demand Across Satellites, Launch Systems, and Space Infrastructure, such as Space Data Centers NEWPORT BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), a diversified holding company, highlights that its current precision manufacturing operating subsidiaries currently serve and have the opportunity to further capitalize of the current Space exploration industry growth.
Frequently Asked Questions
-
What is the current PMGC Holdings Inc. (ELAB) stock price?
-
PMGC Holdings Inc.(NASDAQ:ELAB) stock price is $1.08 in the last trading session. During the trading session, ELAB stock reached the peak price of $309.89474 while $1.02 was the lowest point it dropped to. The percentage change in ELAB stock occurred in the recent session was --3.57% while the dollar amount for the price change in ELAB stock was -$-0.04.
-
ELAB's industry and sector of operation?
-
The NASDAQ listed ELAB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ELAB?
-
Graydon Bensler | Chief Executive Officer, Chief Financial Officer, Secretary & Director
|
|
|
| -
How many employees does ELAB have?
-
Number of ELAB employees currently stands at 34. ELAB operates from 120 Newport Center Drive, Newport Beach, CA 92660, US.
-
Link for ELAB official website?
-
Official Website of ELAB is: https://pmgcholdings.com
-
How do I contact ELAB?
-
ELAB could be contacted at phone #866 445 4886 and can also be accessed through its website. ELAB operates from 120 Newport Center Drive, Newport Beach, CA 92660, US.
-
How many shares of ELAB are traded daily?
-
The average number of ELAB shares traded daily for last 3 months was 3.19M.
-
What is the market cap of ELAB currently?
-
The market value of ELAB currently stands at $2.09M with its latest stock price at $1.08